Join the breakthrough in Long COVID diagnostics with our innovative, rapid molecular test. Discover precision care and contribute to global health solutions. Secure your early access today and be part of the future of healthcare.
The absence of a long COVID (LC) or post-acute sequelae of COVID-19 (PASC) diagnostic has profound implications for research and potential therapeutics given the lack of specificity with symptom-based identification of LC and the overlap of symptoms with other chronic inflammatory conditions. ...
In addition to debates on the nomenclature, there is also uncertainty on diagnostic criteria. There is the scarcity of discussion and proposals for such diagnostic criteria. We found only 1 article focused on the diagnostic criteria. Raveendran’s proposed criteria for Long COVID-19 consisted of 3...
It is also estimated that between 10% and 30% of those who survive COVID-19 develop persistent symptoms after the acute infection has passed. These individuals, who most often experienced initial infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) considered mild to ...
While clinicians are familiar withpost-viral or post-infective syndromes, long COVID is new. There is nodiagnostic test, and it's likely it's really a mixture of different conditions with different underlying causes. Different time-frames are used to define it. According to theAustralian Departm...
Yet its nebulous nature means there isn't yet a definitive, yes-or-no lab test for it. "There's no diagnostic test," said Dr. Jeff Parsonnet, an infectious disease physician who started the Post-Acute COVID Syndrome clinic at Dartmouth Hitchcock Medical Center. "It's really a clinical ...
"These 'long' infections are so difficult to diagnose and treat primarily because of a lack of diagnostic tests and there being so many possible symptoms. There have been more than 200 investigated for long COVID alone." Professor Adrian Martineau, Chief Investigator of COVIDENCE UK and Clinical...
On March 2020, partners of the EU-CardioRNA COST Action network3,4 gathered forces to develop a RNA-based diagnostic test based on artificial intelligence (AI) to predict clinical outcomes after COVID-195. The rationale for this endeavor was that leveraging the power of non-coding RNAs may ...
The frequency of, and risk factors for, long COVID are unclear among community-based individuals with a history of COVID-19. To elucidate the burden and possible causes of long COVID in the community, we coordinated analyses of survey data from 6907 indi
Long-term complications after coronavirus disease 2019 (COVID-19) are common in hospitalized patients, but the spectrum of symptoms in milder cases needs further investigation. We conducted a long-term follow-up in a prospective cohort study of 312 patie